ConcertAI, which specializes in software and real-world evidence for clinical trials, has unveiled the latest version of its clinical trial optimization product.
Dubbed CTO 2.0, the latest version will include tools such as line of therapy assessments; data that integrate electronic medical-derived, medical claims and social determinants of health; site- and investigator-level information on current and previous clinical trials generated from public and private sources; and operational trial metrics and site profile information, the company said in an April 5 press release.
The upgrades are part of ConcertAI’s efforts to expand trial sponsor diversity and inclusion of underrepresented patient groups while also speeding the process of identifying trial sites.
“Meeting these goals requires working with sites and investigators not historically preferred, designing trials for a minimum of burden on research sites and patients and, perhaps most importantly, moving more studies into community-based research settings,” Jeff Elton, ConcertAI’s chief executive, said in the release.
The company’s SaaS technology helps researchers and clinicians target the most appropriate sites for clinical trials and balance potential patients available and previous trial performances at those sites to improve the chances for trial success.
In January, Caris Life Sciences chose ConcertAI for a joint pitch to cancer researchers, clinicians and drug developers. That deal saw Caris’ silo of real-world patient information—including DNA, RNA and protein data as well as the sequencing of tumor mutations—merge with ConcertAI’s collection of cases spanning solid tumors and blood cancers, including the treatment and outcomes of nearly 7 million patients.